Concepedia

Harold Hatch

HH

Statistics

Publications

11

Citations

2K

H-Index

11

Active since

2002

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Harold Hatch is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and molecular oncology.

Publications per year

2002–2018

11

Publications

11

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 938 citations · Full text

, , +17

Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and Survival

Bart Lutterbach, Qinwen Zeng, Lenora J. Davis et al. · Cancer Research · 2007 · 320 citations

, , +17

<i>FGFR2</i> -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

Kaiko Kunii, Lenora J. Davis, Julie Gorenstein et al. · Cancer Research · 2008 · 269 citations

, , +17

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING

Tony Siu, Michael D. Altman, Gretchen A. Baltus et al. · ACS Medicinal Chemistry Letters · 2018 · 172 citations · Full text

, , +14

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

Bo‐Sheng Pan, Grace K.Y. Chan, Mélissa Chénard et al. · Cancer Research · 2010 · 82 citations

, , +17

1–5 of 11